Updated opioid safety labeling is based on new data from two large postmarketing observational studies<\/p>\n<\/h3>\n
By Stephanie Brown HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Aug. 4, 2025 (HealthDay News) — The U.S. Food and Drug Administration announced it will now be requiring updated safety labels for all opioid pain medications to better highlight the risks of long-term use, including misuse, addiction, and overdose.<\/p>\n
The updated FDA opioid safety labeling is based on new data from two large postmarketing observational studies, which showed serious risks from long-term use. Citing these findings, public input, and the lack of strong evidence supporting long-term effectiveness, the FDA is updating opioid safety labels to support treatment decisions based on the latest evidence.<\/p>\n
“The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,” FDA Commissioner Marty Makary, M.D., M.P.H., said in a statement. “This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and postmarket monitoring so that nothing like this ever happens again.”<\/p>\n
The labeling changes will include clearer risk information; stronger dosing warnings; clarified use limits, including removing language that could be misinterpreted as supporting indefinite use; and treatment guidance, emphasizing that long-acting opioids should only be used when other treatments, including short-acting opioids, are ineffective.<\/p>\n
The labels will also address safe discontinuation; overdose reversal agents; drug interactions, including combining opioids with gabapentinoids; additional risks with overdose, highlighting new information on postoverdose toxic leukoencephalopathy; and digestive health, including updates about possible esophageal complications.<\/p>\n
The FDA is also requiring a new randomized, controlled clinical trial to directly assess the benefits and risks of long-term opioid use. The agency says it will closely monitor the trial’s progress.<\/p>\n